New biomarkers for diagnosis and management of polycystic ovary syndrome

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting young women. Even though the definition of PCOS has changed over the years, all diagnostic criteria include two or more of the following: oligomenorrhea/oligoovulation/anovulation, androgen excess and polycystic ovaries (PCO). Traditional method of assessing the ovarian morphology has been transvaginal pelvic ultrasound. Recent studies support that serum anti-Mullerian hormone (AMH) levels correlate with the number of ovarian follicles and cysts. Hence, measurement of AMH is adequate to make the diagnosis. Traditionally, hyperandrogenemia has been assessed by measuring total-testosterone. The literature stresses the importance of sex hormone binding globulin (SHBG) measurements and bioavailable-testosterone and free-testosterone calculations, because insulin resistance decreases SHBG, lowers total-testosterone, and leads to under-estimation of bioavailable- and free-testosterone. Since 50–60% of PCOS patients have metabolic syndrome, assessment of metabolic risk is also necessary. It is important to diagnose insulin resistance before development of glucose intolerance and diabetes. This requires measurements of not only plasma glucose but also insulin concentrations. Determination of HgBA1 can be informative as well. This review aims to present an accurate and cost-effective approach to diagnosis and management of PCOS.

Original languageEnglish (US)
Pages (from-to)248-253
Number of pages6
JournalClinica Chimica Acta
Volume471
DOIs
StatePublished - Aug 1 2017

Fingerprint

Polycystic Ovary Syndrome
Biomarkers
Testosterone
Anti-Mullerian Hormone
Sex Hormone-Binding Globulin
Insulin
Insulin Resistance
Oligomenorrhea
Anovulation
Glucose
Ovarian Cysts
Ovarian Follicle
Glucose Intolerance
Medical problems
Androgens
Ovary
Ultrasonics
Plasmas
Costs and Cost Analysis
Serum

Keywords

  • Anti-Mullerian hormone
  • Polycystic ovary syndrome
  • Sex hormone binding globulin

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

New biomarkers for diagnosis and management of polycystic ovary syndrome. / Karakas, Siddika E.

In: Clinica Chimica Acta, Vol. 471, 01.08.2017, p. 248-253.

Research output: Contribution to journalReview article

@article{c64645bbc7024a72bcb564153ce56aa9,
title = "New biomarkers for diagnosis and management of polycystic ovary syndrome",
abstract = "Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting young women. Even though the definition of PCOS has changed over the years, all diagnostic criteria include two or more of the following: oligomenorrhea/oligoovulation/anovulation, androgen excess and polycystic ovaries (PCO). Traditional method of assessing the ovarian morphology has been transvaginal pelvic ultrasound. Recent studies support that serum anti-Mullerian hormone (AMH) levels correlate with the number of ovarian follicles and cysts. Hence, measurement of AMH is adequate to make the diagnosis. Traditionally, hyperandrogenemia has been assessed by measuring total-testosterone. The literature stresses the importance of sex hormone binding globulin (SHBG) measurements and bioavailable-testosterone and free-testosterone calculations, because insulin resistance decreases SHBG, lowers total-testosterone, and leads to under-estimation of bioavailable- and free-testosterone. Since 50–60{\%} of PCOS patients have metabolic syndrome, assessment of metabolic risk is also necessary. It is important to diagnose insulin resistance before development of glucose intolerance and diabetes. This requires measurements of not only plasma glucose but also insulin concentrations. Determination of HgBA1 can be informative as well. This review aims to present an accurate and cost-effective approach to diagnosis and management of PCOS.",
keywords = "Anti-Mullerian hormone, Polycystic ovary syndrome, Sex hormone binding globulin",
author = "Karakas, {Siddika E}",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.cca.2017.06.009",
language = "English (US)",
volume = "471",
pages = "248--253",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",

}

TY - JOUR

T1 - New biomarkers for diagnosis and management of polycystic ovary syndrome

AU - Karakas, Siddika E

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting young women. Even though the definition of PCOS has changed over the years, all diagnostic criteria include two or more of the following: oligomenorrhea/oligoovulation/anovulation, androgen excess and polycystic ovaries (PCO). Traditional method of assessing the ovarian morphology has been transvaginal pelvic ultrasound. Recent studies support that serum anti-Mullerian hormone (AMH) levels correlate with the number of ovarian follicles and cysts. Hence, measurement of AMH is adequate to make the diagnosis. Traditionally, hyperandrogenemia has been assessed by measuring total-testosterone. The literature stresses the importance of sex hormone binding globulin (SHBG) measurements and bioavailable-testosterone and free-testosterone calculations, because insulin resistance decreases SHBG, lowers total-testosterone, and leads to under-estimation of bioavailable- and free-testosterone. Since 50–60% of PCOS patients have metabolic syndrome, assessment of metabolic risk is also necessary. It is important to diagnose insulin resistance before development of glucose intolerance and diabetes. This requires measurements of not only plasma glucose but also insulin concentrations. Determination of HgBA1 can be informative as well. This review aims to present an accurate and cost-effective approach to diagnosis and management of PCOS.

AB - Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting young women. Even though the definition of PCOS has changed over the years, all diagnostic criteria include two or more of the following: oligomenorrhea/oligoovulation/anovulation, androgen excess and polycystic ovaries (PCO). Traditional method of assessing the ovarian morphology has been transvaginal pelvic ultrasound. Recent studies support that serum anti-Mullerian hormone (AMH) levels correlate with the number of ovarian follicles and cysts. Hence, measurement of AMH is adequate to make the diagnosis. Traditionally, hyperandrogenemia has been assessed by measuring total-testosterone. The literature stresses the importance of sex hormone binding globulin (SHBG) measurements and bioavailable-testosterone and free-testosterone calculations, because insulin resistance decreases SHBG, lowers total-testosterone, and leads to under-estimation of bioavailable- and free-testosterone. Since 50–60% of PCOS patients have metabolic syndrome, assessment of metabolic risk is also necessary. It is important to diagnose insulin resistance before development of glucose intolerance and diabetes. This requires measurements of not only plasma glucose but also insulin concentrations. Determination of HgBA1 can be informative as well. This review aims to present an accurate and cost-effective approach to diagnosis and management of PCOS.

KW - Anti-Mullerian hormone

KW - Polycystic ovary syndrome

KW - Sex hormone binding globulin

UR - http://www.scopus.com/inward/record.url?scp=85020923125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020923125&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2017.06.009

DO - 10.1016/j.cca.2017.06.009

M3 - Review article

VL - 471

SP - 248

EP - 253

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -